Clinical methodologies in the examination of nicotinic effects on cognition

Nicotinic Receptors in the Nervous System

Volumn , Issue , 2001, Pages 261-280

  Potter, Alexandra ^a   Newhouse, Paul A ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34047138228     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (79)

1. Robbe, H.W.J. and O’Hanlon, J.F., Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers, Eur. Neurospsychopharmacol., 5, 35-42, 1995.
2. Newhouse, P.A., Potter, A., and Levin, E.D., Nicotinic system involvement in Alzheimer’s and Parkinson’s diseases, Drugs Aging, 11(3), 206-228. 97.
3. Gotti, C., Fornasari, D., and Clementi, F., Human neuronal nicotinic receptors, Prog. Neurobiol., 53, 199-237, 1997.
4. Arneric, S.P. and Brioni, J.D., Neuronal nicotinic receptors: pharmacology and therapeutic opportunities, in Lukas, R.J., Ed., Cell Lines as Models for Studies of Nicotinic Acetylcholine Receptors, Wiley-Liss, New York, 1998, 81-97.
5. Paterson, D. and Nordberg, A., Neuronal nicotinic receptors in the human brain, Prog. Neurobiol., 61,75-111, 2000.
6. Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., Rosenthal, J., Waldo, M.C., Reimherr, F., Wender, P., Yaw, J., Young, D.A., Breese, C.R., Adams, C., Patterson, D., Adler, L.E., Kruglyak, L., Leonard, S., and Byerley, W., Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus, Proc. Nat. Acad. Sci., 94, 587-592, 1997.
7. Chini B., Raimond E., Elgoyhen A., Moralli D., Balzaretti M., and Heinemann S., Molecular cloning and chromosomal localization of the human α-7 nicotinic receptor subunit gene (CHRNA7), Genomics, 19:379-81, 1994.
8. Steinlein, O.K., Mulley, J.C., Propping, P., Wallace, R.H., Phillips, H.A., Sutherland, G.R., et al., A missense mutation in the neuronal nicotinic acetylcholine receptor α4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy, Nature Genetics, 1995; 11:201-203.
9. Whitehouse, P. J., Martino, A.M., Antuono, P.G., Lowenstein, P.R., Coyle, J.T., Price, D.R., and Kellar, K.J., Nicotinic acetylcholine binding sites in Alzheimer’s disease, Brain Res., 371, 146-151, 1986.
10. Flynn D.D. and Mash, D.C., Nicotine receptors in human frontal and infratemporal cortex: comparison between Alzheimer’s disease and the normal, Neurosci. Abs., 11:1119, 1985.
11. Aubert, I., Araujo, D. M., Cecyre, D., Robitaille, Y., Gauthier, S., and Quirion, R., Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer’s and Parkinson’s diseases, J. Neurochem., 58, 529-541, 1992.
12. Nordberg, A., Functional changes in neuronal nicotinic receptors in Alzheimer’s disease, Behav. Pharmacol., 7 (Suppl. 1), 77-78, 1996.
13. Nordberg A., Clinical studies in Alzheimer patients with positron emission tomography, Behav. Brain Res., 57:215-224, 1993.
14. Maltby, N., Broe, G.A., Creasey, H., Jorm, A.F., Christensen, H., and Brooks, W.S., Efficacy of tacrine and lecithin in mild to moderate Alzheimer’s disease: double-blind trial, Br. Med. J., 308, 879-883, 1994.
15. Nordberg, A., Human nicotinic receptors -- their role in aging and dementia, Neurochem. Int., 25(1), 93-97, 1994.
16. Newhouse, P., Potter, A., and Corwin, J., Effects of nicotinic cholinergic agents on cognitive functioning in Alzheimer’s and Parkinson’s disease, Drug Devel. Res., 38(3/4), 278-289, 1996.
17. Potter A, Corwin J, Lang J, Lenox R, and Newhouse PA. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 improves learning in Alzheimer’s disease, Psychopharmacology, 142:334-342, 1999.
18. Jones, G.M.M., Sahakian, B.J., Levy, R., Warburton, D.M., and Gray, J.A., Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer’s disease, Psychopharmacology, 108, 485-494, 1992.
19. Newhouse, P.A., Potter, A., Corwin, J., and Lenox, R., Acute nicotinic blockade produces cognitive impairment in normal humans, Psychopharmacology, 108, 480-484, 1992.
20. Benwell, M.E.M, Balfour, D.J.K., and Khadra, L.F., Studies on the influence of nicotine infustions on mesolimbic dopamine and locomotor responses to nicotine, J. Neurochem., 72:233-239, 1994.
21. Court, J.A., Lloyd, S., Thomas, N., Piggott, M.A., Marshall, E.F., Morris, C.M., et al., Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use, Neuroscience, 87:63-78, 1998.
22. Whitehouse, P.J., Martino, A.M., Marcus, K.A., Zweig, R.M., Singer, H.S., Price, D.L., and Kellar, K.J., Reductions in acetylcholine and nicotine binding in several degenerative diseases, Arch. Neurol., 45, 722-724, 1988.
23. Kelton, M.C., Kahn, H.J., Conrath, C.L., and Newhouse, P.A., The chronic and acute effects of nicotine on Parkinson’s disease, 1999.
24. Baron, J.A., Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious, Br. Med. J., 52:58-73, 1996.
25. Newhouse, P.A. and Kelton, M., Nicotinic systems in central nervous systems disease: degenerative disorders and beyond, Pharmaceutica Acta Helvetiae, 74, 91-101, 2000.
26. Levin, E.D., Conners, C.K., Sparrow, E., HInton, S.C., Erhardt, D., Meck, W.H., Rose, J.E., and March, J., Nicotine effects on adults with attention-deficit/hyperactivity disorder, Psychopharmacology, 123, 55-63, 1996.
27. Seyler, Jr., L. E., Pomerleau, O.F., Fertig, J.B., Hunt, D., and Parker, K., Pituitary hormone response to cigarette smoking, Pharmacol. Biochem. Behav., 24, 159-163, 1986.
28. Curzon, P., Kim, D.J.B., and Decker, M.W., Effect of nicotine, lobeline, and mecamylamine on sensory gating in the rat, Pharmacol. Biochem. Behav., 49(4), 877-882, 1994.
29. Glassman, A.H., Helzer, J.E., Covey, L.S., Cottler, L.B., Stetner, F., Tipp, J.E., et al., Smoking cessation and major depression, J. Am. Med. Assoc., 264:1546-1549, 1990.
30. Salin-Pascual, R.J. and Drucker-Colin R. A novel effect of nicotine on mood and sleep in major depression, NeuroReport, 9:57-60, 1998.
31. Sanberg, P.R., Silver, A.A., Shytle, R.D., Philipp, M.K., Cahill, D.W., Fogelson, HM., et al. Nicotine for the treatment of Tourette’s syndrome, Pharmac. Ther, 74:21-25, 1997.
32. McConville, B.J., Sanberg, P.R., Fogelson, M.H., King, J., Cirino, P., Parker, K.W., and Norman, A.B., The effects of nicotine plus haloperido compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette’s disorder, Biol. Psych., 31, 832-840, 1992.
33. Dursun, S.M. and Reveley, M.A., Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette’s syndrome: an open study, Psychol. Med., 27:483-487, 1997.
34. Benwell, M.E.M., Balfour, D.J.K., and Anderson, J.M., Evidence that tobacco smoking increases the density of nicotine binding sites in human brain, J. Neurochem., 50:1243-1247, 1988.
35. Piasecki, M. and Newhouse, P., Nicotine in psychiatry: psychopathology and emerging therapeutics, in Zevin S, Benowitz NL, Eds., Pharmacokinetics and Pharmacodynamics of Nicotine, Washington, DC, American Psychiatric Press, Inc., 2000.
36. Hughes, J.R., Hatsukami, D.K., and Skoog, K.P., Physical dependence on nicotine in gum: a placebo substitution trial, J. Am. Med. Assoc., 255(23), 3277-3279, 1986.
37. Anonymous, Behavioral toxicity of nicotine, in Hughes J.R., Ed., Dependence on and Abuse of Nicotine Replacement Medications: An update, 147-157.
38. Hughes, J.R., Observer reports of smoking status: a replication, J. Subst. Abuse, 4, 403-406, 1992.
39. Benowitz, N.L. and Jacob III, P., Nicotine and carbon monoxide intake from highand low-yield cigarettes, Clin. Pharmacol. Ther., 265-270, 1984.
40. Benowitz N.L., Jacob P.I., and Fong I., Nicotine metabolic profile in man: comparison of cigarette smokin and transdermal nicotine, J. Pharmacol. Exp. Ther., 268:296-303, 1994.
41. Pomerleau, O.F., Nicotine and the central nervous system: biobehavioral effects of cigarette smoking, Am. J. Med., 93(Supp 1A), 2S-7S, 1992.
42. Allen, S.S., Hatsukami, D.K., and Christianson, D., Symptomatology and caloric intake during the menstrual cycle in smoking women, J. Subs. Abuse, 8:303-319, 1996.
43. Shytle, R.D., Silver, A.A., Philipp, M.K., McConville, B.J., and Sanberg, P.R., Transdermal nicotine for Tourette’s syndrome, Drug Devel. Res., 38(3/4), 290-298, 1996.
44. Newhouse, P.A., Potter, A., and Lenox, R.H., The effects of nicotinic agents on human cognition: possible therapeutic applications in Alzheimer’s and Parkinson’s diseases, Med. Chem. Res., 2, 628-642, 1993.
45. Perkins, K.A., Baseline-dependency of nicotine effects: a review, Behav. Pharmacol., 10:597-615, 1999.
46. Heishman, S.J., Snyder, F.R., and Henningfield, J.E., Performance, subjective, and physiological effects of nicotine in nonsmokers, Drug Alc. Depen., 34, 11-18, 1993.
47. Newhouse, P.A. and Hughes, J.R., The role of nicotine and nicotinic mechanisms in neuropsychiatric disease, Br. J. Addic., 86, 521-526, 1991.
48. Fagerstrom, K.O., Pomerleau, O., Giordani, B., and Stelson, F., Nicotine may relieve symptoms of Parkinson’s disease, Psychopharmacology, 116,117-119, 94.
49. Parrott, A.C., Individual differences in stress and arousal during cigarette smoking, Psychopharmacology, 115:389-396, 1994.
50. Robbins, T.W., Behavioural determinants of drug action: rate-dependency revisited, in Cooper SJ, editor, Theory in Psychopharmacology, Academic Press, New York, 2-63.
51. Buccafusco, J.J., Prendergast, M.A., Terry, A.V., and Jackson, W.J., Cognitive effects of nicotinic cholinergic receptor agonists in nonhuman primates, Drug Devel. Res., 38(3/4), 196-203, 1996.
52. Newhouse, P.A., Sunderland, T., Tariot, P.N., Blumhardt, C.L., Weingartner, H., Mellow, A., and Murphy, D.L., Intravenous nicotine in Alzheimer’s disease: a pilot study, Psychopharmacology, 95, 171-175, 1988.
53. Kelton, M.C., Kahn, H.J., Conrath, C.L., and Newhouse, P.A., The effects of nicotine on Parkinson’s disease, Brain Cognit., 43, 274-282, 2000.
54. Benowitz, N.L., Jacob III, P., Jones, R.T., and Rosenberg, J., Interindividual variability in the metabolism and cardiovascular effects of nicotine in man, J. Pharmacol. Exp. Ther., 221, 368-372, 1982.
55. Heishman, S.J., Snyder, F.R., and Henningfield, J.E., Performance, subjective, and physiological effects of nicotine in nonsmokers, Drug Alc. Depend., 34(1), 11-18, 1993.
56. Benowitz, N.L., Jacob III, P., and Savanapridi, C., Determinants of nicotine intake while chewing nicotine polacrilex gum, Clin. Pharmacol. Ther., 41(4), 467-473. 87.
57. Russell, M.A.H., Jarvis, M.J., Jones, G., and Feyerabend, C., Nonsmokers show acute tolerance to subcutaneous nicotine, Psychopharmacology, 102, 56-58, 1990.
58. Heishman, S.J., Taylor, R.C., and Henningfield, J.E., Nicotine and smoking: a review of effects on human performance, Exp. Clin. Psychopharmacol., 2(4), 345-395, 1994.
59. Snyder, F.R. and Henningfield, J.E., Effects of nicotine administration following 12 h of tobacco deprivation: assessment on computerized performance tasks, Psychopharmacology, 97, 17-22, 1989.
60. Rusted, J.M., Newhouse, P.A., and Levin, E.D., Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer’s disease and Parkinson’s disease, Behav. Brain Res., 113, 121-129, 2000.
61. Manacuso, G., Andres, P., Ansseau, M., and Tirelli, E., Effects of nicotine administered via a transdermal delivery system on vigilance: a repeated measure study, Psychopharmacology, 142, 18-23, 1999.
62. Conners, C.K., Levin, E.D., Sparrow, E., Hinton, S.C., Erhardt, D., Meck, W.H., Rose, J.E., and March, J., Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD), Psychopharmacol. Bull., 32(1), 67-73, 1996.
63. White, H.K. and Levin, E.D., Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer’s disease, Psychopharmacology, 143, 158-165, 1999.
64. Provost, S.C. and Woodward, R., Effects of nicotine gum on repeated administration of the Stroop test, Psychopharmacology, 104, 536-540, 1991.
65. Wesnes, K. and Warburton, D.M., Effects of scopolamine and nicotine on human rapid information processing performance, Psychopharmacology, 82, 147-150, 1984.
66. Prendergast, M.A., Jackson, W.J., Terry, Jr., A.V., Decker, M.W., Arneric, S.P., and Buccafusco, J.J., Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys, Psychopharmacology, 136, 50-58, 1998.
67. Levin, E.D., Conners, C.K., Sparrow, E., HInton, S.C., Erhardt, D., Meck, W.H., Rose, J.E., and March, J., Nicotine effects on adults with attention-deficit/hyperactivity disorder, Psychopharmacology, 123, 55-63, 1996.
68. Sahakian, B., Jones, G., Levy, R., Gray, J., and Warburton, D., The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type, Br. J. Psych., 154, 797-800, 1989.
69. Levin, E.D., Wilson, W., Rose, J.E., and McEvoy, J., Nicotine-haloperidol interactions and cognitive performance in schizophrenics, Neuropsychopharmacology, 15(5), 429-436, 1996.
70. Newhouse, P.A., Potter, A., Corwin, J., and Lenox, R., Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior, Neuropsychopharmacology, 10(2), 93-107, 1994.
71. Wilson, A.L., Langley, L.K., Monley, J., Bauer, T., Rottunda, S., McFalls, E., Kovera, C., and McCarten, J.R., Nicotine patches in Alzheimer’s disease: pilot study on learning, memory, and safety, Pharmacol. Biochem. Behav., 51(2), 509-514, 1995.
72. Warburton, D.M. and Rusted, J.M., Cholinergic control of cognitive resources, Neuropsychobiology, 28, 43-46, 1993.
73. Rusted, J., Graupner, L., O’Connell, N., and Nicholls, C., Does nicotine improve cognitive function, Psychopharmacology, (115), 547-549, 1994.
74. Elrod, K., Buccafusco, J.J., and Jackson, W.J., Nicotine enhances delayed matchingto-sample performance by primates, Life Sci., 43, 277-287, 1988.
75. Perryman, K.M. and Fitten, L.J., Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer’s disease, Life Sci., 53, 479-486, 1993.
76. Newhouse, P.A., Potter, A., Corwin, J., and Lenox, R., Modeling the nicotinic receptor loss in dementia using the nicotinic antagonist mecamylamine: effects on human cognitive functioning, Drug Devel. Res., 31(1), 71-79, 1994.
77. Nordberg, A., Clinical studies in Alzheimer patients with positron emission tomography, Behav. Brain Res., 57, 215-224, 1993.
78. Linville, D.G., Williams, S., Raszkiewicz, J.L., and Arneric, S.P., Nicotinic agonists modulate basal forebrain control of cortical cerebral blood flow in anesthetized rats, J. Pharmacol. Exp. Ther., 267(1), 440-448, 1993.
79. Volkow, N.D., Ding, Y-S, Fowler, J.S., and Gatley, S.J., Imaging brain cholinergic activity with position emission tomography: its role in the evaluation of cholinergic treatment in Alzheimer’s dementia, 49, 211-220, 2001.